Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (361-370 of 1,126) with videos related to

Pageof 113
Sort By:
Future Oncology (London, England)|October 25, 2024
The TALAPRO-3 study design: a plain language summaryNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
European Urology|October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapyPeter F A Mulders, Arturo Molina, Michael Marberger, et al.
European Urology|November 13, 2007
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 menClaudio Jeldres, Nazareno Suardi, Jochen Walz, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 23, 2021
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian contextMichael P Kolinsky, Karen Y Niederhoffer, Edmond M Kwan, et al.
European Urology|June 13, 2020
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL TrialAndrew J Armstrong, Ping Lin, Bertrand Tombal, et al.
Urologic Oncology|November 18, 2025
Partial vs. radical nephrectomy in pT3a renal cancer: Cancer-specific mortality according to fat invasion patternMichele Nicolazzini, Calogero Catanzaro, Federico Polverino, et al.
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
The American Journal of Pathology|June 17, 2019
CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient PrognosisMatthew Dankner, Véronique Ouellet, Laudine Communal, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 2, 2025
Examining the association between real-world extended vs. standard pelvic lymph node dissection and early and late oncologic outcomes in men undergoing radical prostatectomyWyatt MacNevin, Sandra Seo Young Kim, Ricardo A Rendon, et al.
Endocrine Connections|January 24, 2019
Discordance between testosterone measurement methods in castrated prostate cancer patientsMélanie Rouleau, Francis Lemire, Michel Déry, et al.
Pageof 113

Showing results (361-370 of 1,126) with videos related to

Sort By:
Pageof 113
Future Oncology (London, England)|October 25, 2024
The TALAPRO-3 study design: a plain language summaryNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
European Urology|October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapyPeter F A Mulders, Arturo Molina, Michael Marberger, et al.
European Urology|November 13, 2007
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 menClaudio Jeldres, Nazareno Suardi, Jochen Walz, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 23, 2021
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian contextMichael P Kolinsky, Karen Y Niederhoffer, Edmond M Kwan, et al.
European Urology|June 13, 2020
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL TrialAndrew J Armstrong, Ping Lin, Bertrand Tombal, et al.
Urologic Oncology|November 18, 2025
Partial vs. radical nephrectomy in pT3a renal cancer: Cancer-specific mortality according to fat invasion patternMichele Nicolazzini, Calogero Catanzaro, Federico Polverino, et al.
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
The American Journal of Pathology|June 17, 2019
CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient PrognosisMatthew Dankner, Véronique Ouellet, Laudine Communal, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 2, 2025
Examining the association between real-world extended vs. standard pelvic lymph node dissection and early and late oncologic outcomes in men undergoing radical prostatectomyWyatt MacNevin, Sandra Seo Young Kim, Ricardo A Rendon, et al.
Endocrine Connections|January 24, 2019
Discordance between testosterone measurement methods in castrated prostate cancer patientsMélanie Rouleau, Francis Lemire, Michel Déry, et al.
Pageof 113